Real-life Data on Cefiderocol Efficacy and Safety to Treat Multidrug-Resistant Acinetobacter baumannii Infections
Rattachement africain : it. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Background: infections. Methods: This was a retrospective monocentric study including patients hospitalized (>24 hours) at Policlinico Tor Vergata, Rome, Italy, between May 1, 2021, and September 1, 2022, treated with cefiderocol (>48 hours). The primary objective was early clinical improvement at 48-72 hours from cefiderocol start; secondary objectives were clinical success (composite outcome of infection resolution and 14-day survival), breakthrough infection, overall 30-day mortality, and cefiderocol-related adverse events. Results: Eleven patients were enrolled; 91% males (10/11), with a median age (interquartile range [IQR]) of 69 (59-71) years, 91% had ≥1 comorbidity, and 72.7% (8/11) were hospitalized in internal medicine wards. Six patients with bloodstream infection (54.5%; 4 primary, 2 central line-associated), 2 with pneumonia (18.2%), 2 with urinary tract infections (18.2%), and 1 with intra-abdominal infection (9.1%) were treated. Four patients (36.3%) presented with septic shock at cefiderocol start. Cefiderocol was used as monotherapy in 3/11 patients (27.3%), was combined with colistin in all the other 8 cases, and was used in triple combination with tigecycline in 2 patients. The median duration of treatment (IQR) was 12 (10-14) days. Early clinical improvement was documented in 8/11 patients (72.7%), clinical success in 8/11 patients (72.7%). Overall 30-day mortality was 27.3% (3/11), with death occurring a median (IQR) of 19 (17.5-20.5) days after the start of therapy. No cefiderocol-related adverse events were documented. Conclusions: infections.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé, mais le titre doit être comparé manuellement.
- Titre Crossref
- Real-life Data on Cefiderocol Efficacy and Safety to Treat Multidrug-Resistant <i>Acinetobacter baumannii</i> Infections
- Date Crossref
- 01/12/2023
- Éditeur
- Oxford University Press (OUP)
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
University of Rome Tor Vergata pays non établi dans la noticeUniversité ou école supérieure
-
Policlinico Tor Vergata pays non établi dans la noticeÉtablissement de santé
-
Tor Vergata University Department of Systems Medicine pays non établi dans la noticeUniversité ou école supérieure
-
Infectious Diseases Clinic pays non établi dans la noticeÉtablissement de santé
-
Laboratory of Clinical Microbiology pays non établi dans la noticeStructure de recherche
-
Hospital Pharmacy pays non établi dans la noticeÉtablissement de santé
University of Rome Tor Vergata, Policlinico Tor Vergata et Department of Systems Medicine — Tor Vergata University, avec 3 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.